BRCA1 and ovarian carcinoma: While veliparib is not yet approved to treat ovarian cancer, a statistically significant increase in PFS was reported in patients with BRCA1/2-mutated diseases who were treated with the “veliparib throughout” regimen, consisting of carboplatin and paclitaxel plus veliparib followed by veliparib maintenance [18].